Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

327.94USD
15 Dec 2017
Change (% chg)

$4.39 (+1.36%)
Prev Close
$323.55
Open
$328.61
Day's High
$330.06
Day's Low
$322.87
Volume
1,054,357
Avg. Vol
476,607
52-wk High
$348.65
52-wk Low
$244.31

Select another date:

Mon, Dec 4 2017

BRIEF-Biogen Appoints Mark Hernon As SVP, Chief Information Officer

* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage:

BRIEF-Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock

* SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING Source text: (http://bit.ly/2niyLpi) Further company coverage:

Biogen boosts multiple sclerosis holding with Alkermes license

Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

Biogen boosts multiple sclerosis holding with Alkermes license

Nov 27 Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera.

BRIEF-Biogen appoints Jeff Capello as executive vice president and chief financial officer

* Appoints Jeff Capello as executive vice president and chief financial officer

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

BRIEF-Biogen presents new data from long-term extension of phase 1B study

* Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab

Biogen dives as Spinraza U.S. sales miss estimates

Biogen Inc's shares dived 8 percent on Tuesday after U.S. sales of Spinraza, a potential blockbuster drug it is banking on to offset slowing sales of multiple sclerosis drugs, fell short of Wall Street estimates in the latest quarter.

UPDATE 4-Biogen dives as Spinraza U.S. sales miss estimates

* Shares fall as much as 8.14 pct in early trading (Adds details of payment to Neurimmune related to Aducanumab, updates shares)

BRIEF-Biogen Q3 earnings per share $5.79

* Biogen Inc - ‍company restructures collaboration arrangements with eisai and neurimmune to improve long-term value of aducanumab​

Select another date: